In short
This article discusses the ongoing clinical trials of 68Ga-DPI-4452, a novel radiopharmaceutical being studied for its potential in diagnosing and treating advanced or metastatic solid tumors. The trials aim to assess the safety, tolerability, and imaging characteristics of 68Ga-DPI-4452, as well as the safety, tolerability, and efficacy of its therapeutic counterpart, 177Lu-DPI-4452, in patients with specific types of cancer, including clear cell renal cell carcinoma, pancreatic ductal adenocarcinoma, and colorectal cancer.
At a glance
- Study Type
- Phase 1/2, multicenter, open-label, non-randomized
- Investigational Drugs
- [68Ga]Ga-DPI-4452 and [177Lu]Lu-DPI-4452
- Target Conditions
- Unresectable locally advanced or metastatic solid tumors (ccRCC, PDAC, CRC)
- Primary Objectives
- Evaluate safety, tolerability, imaging characteristics, and efficacy
- Key Eligibility Criteria
- Confirmed diagnosis, measurable disease, adequate organ function
- Primary Endpoints
- Adverse events, dose-limiting toxicities, objective response rate
- Secondary Endpoints
- Pharmacokinetics, dosimetry, tumor uptake, progression-free survival
What is 68Ga-DPI-4452?
68Ga-DPI-4452 is an investigational drug being studied for its potential use in patients with advanced or metastatic solid tumors. It is classified as a radiopharmaceutical, which means it contains a radioactive substance used for diagnostic or therapeutic purposes in medicine. The drug is also known by its product name "Debio 0328" and is being developed by Debiopharm.
How does 68Ga-DPI-4452 work?
68Ga-DPI-4452 is designed to target a specific protein called Carbonic Anhydrase IX (CA IX). This protein is often found in higher amounts in certain types of cancer cells. The drug combines a targeting molecule that seeks out CA IX with a radioactive element (Gallium-68). This combination allows doctors to see where the drug accumulates in the body, potentially highlighting areas where cancer is present.
What conditions does 68Ga-DPI-4452 treat?
The clinical trial is investigating the use of 68Ga-DPI-4452 in patients with the following types of advanced or metastatic solid tumors:
- Clear cell renal cell carcinoma (ccRCC): A type of kidney cancer
- Pancreatic ductal adenocarcinoma (PDAC): A type of pancreatic cancer
- Colorectal Cancer (CRC): Cancer that starts in the colon or rectum
These cancers are considered "unresectable locally advanced or metastatic," which means they cannot be completely removed by surgery and may have spread to other parts of the body.
Clinical Trial Overview
The clinical trial for 68Ga-DPI-4452 is a Phase 1/2 study, which means it's in the early stages of testing in humans. The trial has multiple parts:
- Part A: This part focuses on evaluating the safety and how well the body tolerates a single dose of 68Ga-DPI-4452.
- Part B: This part aims to determine the best dose of a related drug called 177Lu-DPI-4452 for each type of cancer being studied.
- Part C: This part will look at how effective 177Lu-DPI-4452 is at fighting the cancer.
Who can participate in the trial?
The trial has specific criteria for who can participate. Some key points include:
- Patients must have confirmed advanced or metastatic ccRCC, PDAC, or CRC.
- Patients must have measurable disease according to specific criteria (RECIST v1.1).
- Patients must have adequate bone marrow, liver, and kidney function.
- For Parts B and C, patients must have a life expectancy of more than 6 months.
There are also several factors that would prevent someone from participating, such as certain medical conditions or previous treatments.
What to expect during the trial
During the trial, participants will receive 68Ga-DPI-4452 through an intravenous (IV) injection, which means it's given directly into a vein. Depending on which part of the trial they're in, participants may also receive 177Lu-DPI-4452.
Throughout the study, doctors will monitor participants closely. They will perform various tests and scans to see how the drug is working and to check for any side effects. These may include:
- Blood and urine tests
- PET/CT scans (a type of imaging that can show where the drug is in the body)
- Monitoring of vital signs and heart activity (ECG)
- Assessments of how the tumor is responding to treatment
Potential Benefits and Risks
As with any clinical trial, there are potential benefits and risks to participating:
Potential Benefits:
- Access to a new treatment that may be effective against your cancer
- Close monitoring by healthcare professionals
- Contributing to medical research that may help future patients
Potential Risks:
- Side effects from the drug, which are not yet fully known
- The treatment may not be effective for your cancer
- Time commitment for study visits and procedures
It's important to discuss these potential benefits and risks with your doctor and the study team before deciding to participate in any clinical trial.